{"analyses":[{"ciLowerLimit":"0.53","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.19","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.79"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.61","upperLimit":"34.40","value":"24.87"},{"groupId":"OG001","lowerLimit":"17.91","upperLimit":"27.56","value":"21.39"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"71"}],"units":"Participants"}],"description":"The time between the date of randomization and the date of death due to any cause. OS will be censored on the last date a participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab:\n\n* Cycles 1 through 4: 240 mg IV Days 1, 15 of each 28-day cycle.\n* Cycles 5 and beyond: 480 mg IV Day 1 of each 28-day cycle.\n\nPomalidomide:\n\n\\- 4 mg PO QD Days 1-21 of each 28-day cycle.\n\nDexamethasone:\n\n* Participants \\</= 75 years old: 40 mg PO Days (1, 8, 15, and 22) of each cycle\n* Participants \\> 75 years old: 20 mg PO Days (1, 8, 15, and 22) of each cycle.","id":"OG000","title":"Arm A: N-Pd"},{"description":"Pomalidomide:\n\n\\- 4 mg PO QD Days 1-21 of each 28-day cycle.\n\nDexamethasone:\n\n* Participants \\</= 75 years old: 40 mg PO Days (1, 8, 15, and 22) of each cycle\n* Participants \\> 75 years old: 20 mg PO Days (1, 8, 15, and 22) of each cycle.","id":"OG001","title":"Arm B: Pd"}],"paramType":"MEDIAN","populationDescription":"All randomized participants in Arm A and B. Data was pre-specified to be collected only in the N-Pd and Pd arms.","reportingStatus":"POSTED","timeFrame":"From randomization to the date of death due to any cause (up to approximately 64 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}